These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25835481)

  • 1. Landscape of current and emerging cell therapy clinical trials in the UK: current status, comparison to global trends and future perspectives.
    Bisson I; Green E; Sharpe M; Herbert C; Hyllner J; Mount N
    Regen Med; 2015; 10(2):169-79. PubMed ID: 25835481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cell Therapy Catapult: growing a U.K. cell therapy industry generating health and wealth.
    Thompson K; Foster EP
    Stem Cells Dev; 2013 Dec; 22 Suppl 1():35-9. PubMed ID: 24304073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation for stroke.
    Roitberg B
    Neurol Res; 2004 Apr; 26(3):256-64. PubMed ID: 15142317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New guidance on codes of practice, standardized methods and regulations for cell-based therapeutics.
    Harris N; Munro C; Patel B
    Regen Med; 2006 Sep; 1(5):705-7. PubMed ID: 17465738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulating cell-based regenerative medicine: the challenges ahead.
    Ali RR; Hollander AP; Kemp P; Webster A; Wilkins MR
    Regen Med; 2014 Jan; 9(1):81-7. PubMed ID: 24351008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The translation of cell-based therapies: clinical landscape and manufacturing challenges.
    Heathman TR; Nienow AW; McCall MJ; Coopman K; Kara B; Hewitt CJ
    Regen Med; 2015; 10(1):49-64. PubMed ID: 25562352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunities and challenges for the cellular immunotherapy sector: a global landscape of clinical trials.
    Bonter K; Breckenridge Z; Lachance S; Delisle JS; Bubela T
    Regen Med; 2017 Sep; 12(6):623-636. PubMed ID: 28850001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy: opportunities, risks and future perspectives.
    Hildebrandt M; Peggs K; Uharek L; Bollard CM; Heslop HE
    Cytotherapy; 2014 Apr; 16(4 Suppl):S120-9. PubMed ID: 24629797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global update: UK.
    Culme-Seymour EJ
    Regen Med; 2012 Nov; 7(6 Suppl):136-8. PubMed ID: 23210827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CellCAN: a unique enabler of regenerative medicine and cell therapy in Canada.
    Roy DC; Alarco AM; Isasi R
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():24-8. PubMed ID: 25457957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential benefits of cell therapy in coronary heart disease.
    Grimaldi V; Mancini FP; Casamassimi A; Al-Omran M; Zullo A; Infante T; Napoli C
    J Cardiol; 2013 Nov; 62(5):267-76. PubMed ID: 23834957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.
    Henick BS; Herbst RS; Goldberg SB
    Expert Opin Ther Targets; 2014 Dec; 18(12):1407-20. PubMed ID: 25331677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the 'Clinical Trials' directive on the cost and conduct of non-commercial cancer trials in the UK.
    Hearn J; Sullivan R
    Eur J Cancer; 2007 Jan; 43(1):8-13. PubMed ID: 17118647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of registration of clinical trials units: the UK experience.
    McFadden E; Bashir S; Canham S; Darbyshire J; Davidson P; Day S; Emery S; Pater J; Rudkin S; Stead M; Brown J
    Clin Trials; 2015 Apr; 12(2):166-73. PubMed ID: 25475881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organizational profile: UK regenerative medicine platform immunomodulation hub.
    Asante CO
    Regen Med; 2015; 10(3):259-63. PubMed ID: 25933235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
    H Yi D; Appel S
    Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J; Mackiewicz A
    Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.